Moderna Inc. is looking to move its coronavirus vaccine candidate mRNA-1273 rapidly into Phase II trials.
The company has become one of the frontrunners in the race to develop a vaccine, despite its mRNA-based platform being...
Coronavirus Update: Moderna Prepares For Crucial Phase II Trial Of Vaccine, Japan Takes Steps
At Risk Age Groups Added To Phase I Studies
Listen to this article
Plus: Japan pledges rapid approval for remdesivir, GSK launches fund to look into impact of coronavirus on people with HIV.
Keep up with the top pharma business news of the week. On the go.
More from COVID-19
• By
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
• By
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
• By
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
• By
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
More from Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains